Novartis’ Jakavi bests current therapy for GvHD by Selina McKee | Apr 23, 2020 | News | 0 REACH2 is the first Phase III study in steroid-refractory acute graft-versus-host-disease (GvHD) to have met its primary endpoint Read More
Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm by Selina McKee | Apr 3, 2020 | News | 0 Early clinical evidence suggests that the JAK inhibitor could reduce the number of patients requiring intensive care and mechanical ventilation Read More
SMC green light for rare blood cancer treatment by Selina McKee | Dec 10, 2019 | News | 0 NHS funding was backed for four medicines Read More
Novartis’ Jakavi comes out on top in rare blood cancer trial by Selina McKee | Jun 13, 2016 | News | 0 New data shows Novartis’ Jakavi to be superior than best available therapy in patients with the rare haematological cancer polycythemia vera (PV), which affects around 100,000 people globally a year. Read More